Provention Bio Inc (NASDAQ:PRVB)

9.29
Delayed Data
As of Nov 28
 -0.20 / -2.11%
Today’s Change
3.19
Today|||52-Week Range
9.85
+65.30%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$828.3M

Company Description

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Contact Information

Provention Bio, Inc.
55 Broad Street
Red Bank New Jersey 07701-1902
P:(908) 428-9136
Investor Relations:

Employees

Shareholders

Other institutional37.19%
Individual stakeholders16.25%
Mutual fund holders12.18%

Top Executives

Ashleigh W. PalmerChief Executive Officer & Director
Christina YiChief Operating Officer
Thierry ChaucheChief Financial Officer
Francisco LeonChief Scientific Officer
Eleanor Leni RamosChief Medical Officer